How to Fight Insurance Denials for Atopic Dermatitis Treatment

Atopic dermatitis (AD, also called eczema) is a chronic inflammatory skin disease affecting millions of Americans. Modern biologic and JAK-inhibitor therapies like Dupixent, Adbry, Ebglyss, Rinvoq, Cibinqo, and Nemluvio can transform lives—but insurers frequently deny them, citing step therapy, "not medically necessary," or insufficient documentation. This happens even when topical steroids, calcineurin inhibitors, and phototherapy have failed or caused side effects. Denials are common because these drugs cost $40,000–$80,000 per year, and payers apply rigid step-edits or demand scoring thresholds that don't match how the disease actually affects patients—especially when it involves the face, eyelids, hands, or genitals, or causes sleep-destroying itch. This guide walks you through the most common denial templates, the clinical evidence insurers respect, and the concrete steps to overturn each type of denial.

---

Why Insurers Deny Atopic Dermatitis Therapies

1. Step therapy / fail-first mandate

The insurer demands documented trials of multiple topical corticosteroids (often specifying "high-potency" like clobetasol), topical calcineurin inhibitors (tacrolimus or pimecrolimus), and sometimes phototherapy (narrow-band UVB) or off-label oral immunosuppressants (cyclosporine, methotrexate). You may be denied a biologic or JAK inhibitor until you've "failed" each step, even when those steps caused side effects (skin atrophy, burning, renal toxicity) or aren't feasible (phototherapy requires 2–3 visits/week, often impossible for pediatric or rural patients).

2. Insufficient disease severity

The plan requires specific numeric thresholds: Investigator's Global Assessment (IGA) ≥3 (moderate) or 4 (severe), Eczema Area and Severity Index (EASI) ≥16 or ≥21, Body Surface Area (BSA) ≥10%, or Pruritus Numeric Rating Scale (NRS) ≥4. If your denial letter says "does not meet severity criteria," the insurer either didn't see these scores or disputes that your disease qualifies—even though quality of life and special-site involvement (face, eyelids, hands, genitals) may be catastrophic at lower BSA.

3. "Not medically necessary" or "experimental/investigational"

This language appears when the insurer claims the treatment isn't supported by guidelines, or when a drug is FDA-approved but your plan's medical policy lags behind. For example, Ebglyss (lebrikizumab) was approved in September 2024, Nemluvio (nemolizumab) for AD in December 2024, and Zoryve foam for AD in August 2024; older medical policies may not yet list them.

4. Age or weight restrictions

Biologics have staggered approvals: Dupixent is FDA-approved for ages 6 months and up (June 2022 for 6 mo–5 yr, May 2020 for 6–11 yr, March 2019 for 12–17, March 2017 for adults), but some plans require age ≥12 or ≥18. Ebglyss is approved for ages 12+ and weight ≥40 kg; Nemluvio for AD is ages 12+; Cibinqo and Rinvoq for AD are FDA-approved ages 12+ (February 2023 and April 2022 pediatric expansions). Insurers may deny coverage for younger children even when FDA labeling permits it.

5. Duplicate biologic or "not the preferred agent"

If you previously tried Dupixent (IL-4Rα blockade) and it didn't work or caused conjunctivitis, the insurer may still deny Adbry or Ebglyss (both IL-13 specific) on grounds that "patient already tried a biologic." Conversely, some plans prefer Dupixent first because it has the longest track record, and require documented Dupixent failure before covering Adbry, Ebglyss, or Nemluvio. JAK inhibitors (Cibinqo, Rinvoq, Opzelura) may be restricted to third- or fourth-line because of boxed warnings (serious infections, malignancy, thrombosis, cardiovascular events).

---

The Citations Insurers Respect

When you appeal, referencing the exact guidelines, consensus documents, and pivotal trials—by name and year—signals that your case is clinically grounded. Here are the key sources for atopic dermatitis:

• American Academy of Dermatology (AAD) Guidelines for Management of Atopic Dermatitis, 2014 (still referenced; updates ongoing; cite specific recommendations on systemic therapy when topical/phototherapy inadequate).
• AAD Atopic Dermatitis Practice Update, Part 2: Systemic Therapies (J Am Acad Dermatol 2023) — covers biologics, JAK inhibitors, and off-label immunosuppressants.
• European Academy of Dermatology and Venereology (EADV) / European Task Force on Atopic Dermatitis (ETFAD) Guidelines 2020 — supports early systemic therapy for moderate-severe AD, acknowledges inadequacy of topical monotherapy.
• National Eczema Association (NEA) consensus statements and severity scoring tools — IGA, EASI, POEM, DLQI/CDLQI validated instruments.
• FDA prescribing information / approval dates:

- Dupixent ages 6 mo+ (June 2022), 6–11 (May 2020), 12–17 (March 2019), adult (March 2017)

- Adbry adult (December 2021), ages 12+ (December 2023)

- Ebglyss ages 12+ and ≥40 kg (September 2024)

- Nemluvio for AD ages 12+ (December 2024; prurigo nodularis approval August 2024)

- Cibinqo adult (January 2022), ages 12+ (February 2023)

- Rinvoq for AD adult (January 2022), ages 12+ (April 2022)

- Opzelura ages 12+ (September 2021, short-term/non-continuous use)

- Eucrisa ages 3 mo+ (December 2016)

- Zoryve foam for AD ages 9+ (August 2024)

• Pivotal trials (cite when arguing efficacy):

- Dupixent: SOLO-1 and SOLO-2 (monotherapy), CHRONOS (with TCS), LIBERTY AD PEDS (pediatric), all published in NEJM, Lancet, J Allergy Clin Immunol.

- Adbry: ECZTRA-1, ECZTRA-2, ECZTRA-3 (NEJM 2021; Lancet 2021).

- Ebglyss: ADhere (NEJM 2024), ADvocate-1 and ADvocate-2.

- Nemluvio: ARCADIA-1 and ARCADIA-2 (NEJM 2024 for prurigo nodularis; AD trials published 2024).

- Cibinqo: JADE MONO-1, JADE MONO-2, JADE COMPARE (Lancet 2021; NEJM 2021).

- Rinvoq: Measure Up 1, Measure Up 2, AD Up (NEJM 2021; Lancet 2021).

• Topical corticosteroid and calcineurin inhibitor evidence base — referenced in AAD/EADV guidelines; document trial durations, potency classes (I–VII for steroids), and adverse events (atrophy, striae, tachyphylaxis, burning with TCI).
• Phototherapy evidence — NB-UVB consensus statements (AAD 2010 phototherapy guidelines); acknowledge when access barriers (pediatric, rural, time) or plateau response limit utility.
• Off-label systemic immunosuppressants — cyclosporine, methotrexate, azathioprine, mycophenolate mofetil are supported by AAD/EADV guidelines and expert consensus (J Am Acad Dermatol systematic reviews); note boxed warnings and renal/hepatic/hematologic monitoring requirements.

If your denial letter cites an internal "medical policy," request a copy and check its reference list. Often the policy will cite the same AAD or EADV guidelines but cherry-pick language. Your appeal should quote the full guideline text in context.

---

How to Argue Against Each Denial Reason

1. Fighting "step therapy not completed"

Concrete steps:

• List every topical trial with drug name, potency/class, duration, frequency, outcome, and adverse events. Example: "Triamcinolone 0.1% (class III) twice daily for 12 weeks—partial flare control, recurrent rebound within 5 days of discontinuation. Clobetasol 0.05% (class I) twice daily for 4 weeks—improved but developed skin atrophy and striae in bilateral antecubital fossae, discontinued per AAD guidance on chronic high-potency use. Tacrolimus 0.1% ointment twice daily for 16 weeks—burning and stinging intolerance, patient unable to tolerate. Pimecrolimus 1% cream twice daily for 8 weeks—inadequate response. Eucrisa 2% twice daily for 8 weeks—minimal benefit, EASI remained ≥25. Opzelura 1.5% twice daily for 8 weeks—partial response, but FDA label restricts to short-term/non-continuous use, not viable for chronic maintenance."
• Document phototherapy trial and barriers. "NB-UVB 30 sessions over 12 weeks (August–November 2024), 2×/week then 3×/week. EASI improved from 28 to 18 but plateaued; developed hyperpigmentation. Drive time 90 minutes each direction (rural location); patient missed 6 sessions due to work/school. Pediatric patient age 8—parent unable to sustain 3 sessions/week schedule. Barrier documented by dermatologist letter [attach]."
• For oral immunosuppressants (if required by plan): "Cyclosporine 3 mg/kg/day for 6 months (2023)—EASI improved 28→9, but serum creatinine rose 0.9→1.3 mg/dL and blood pressure 145/95; discontinued per AAD guidance (maximum duration ≤1 year due to renal and cardiovascular toxicity, boxed warning). Methotrexate 15 mg weekly for 4 months—partial response, developed transaminitis (ALT 98), stopped. Patient has now exhausted topical, phototherapy, and first-line systemic options per AAD 2023 systemic therapy algorithm."
• Cite AAD / EADV language: "AAD 2023 systemic therapy update states that when topical corticosteroids and calcineurin inhibitors are insufficient or cause limiting adverse effects, and phototherapy is impractical or ineffective, biologic therapy is appropriate for moderate-to-severe AD. Patient meets criteria."

Key point: Insurers often count "trials" only if you used the drug long enough at adequate dose and documented why you stopped. Vague letters ("patient failed topicals") will be rejected. Your dermatologist's appeal letter must be a timeline with outcomes and adverse events.

---

2. Fighting "insufficient disease severity"

Concrete steps:

• Include validated scoring at the time of the denial. "At time of biologic request (date): IGA 4 (severe). EASI 28.4 (head 4.2, upper-limb 8.0, trunk 8.6, lower-limb 7.6), exceeding plan threshold of EASI ≥21. BSA 42%, exceeding plan threshold of ≥10%. Pruritus NRS 9/10 (worst itch in past 24 hours), exceeding plan threshold of ≥4. DLQI score 24 (extremely large effect on quality of life), exceeding plan threshold of ≥11. Sleep disturbance 6 nights per week due to nocturnal pruritus."
• Highlight special-site involvement. "Plan policy may emphasize total BSA, but AAD and EADV guidelines recognize that face, eyelid, hand, and genital involvement cause disproportionate impairment regardless of BSA. Patient has bilateral eyelid dermatitis (risk of ocular complications), hand dermatitis (functional impairment, unable to work as nurse due to recurrent fissuring), and flexural/genital involvement (DLQI subdomain sexual-difficulties score 3/3). FDA Dupixent label and pivotal SOLO trials enrolled patients with head-and-neck AD and hand AD as high-impact phenotypes."
• Attach photos with date stamps (if patient consents; ensure face obscured if needed for privacy). Dermatology notes with body diagrams showing distribution.
• Cite the guideline: "EADV 2020 guidelines state that disease severity should be assessed using validated tools (IGA, EASI, DLQI) and patient-reported outcomes (pruritus NRS, sleep loss, quality-of-life impact). This patient meets or exceeds every numeric threshold in the plan policy."

Key point: If the insurer says "severity scores not documented," it means the prior authorization form or physician's letter omitted them. The appeal must include a table of scores with dates. Many offices forget to document pruritus NRS and DLQI—these are often the strongest data points because they directly measure suffering.

---

3. Fighting "not medically necessary" or "experimental/investigational"

Concrete steps:

• Confirm FDA approval status and date. "Ebglyss (lebrikizumab) received FDA approval September 17, 2024 for moderate-to-severe atopic dermatitis in patients aged 12 years and older weighing at least 40 kg, based on ADvocate-1, ADvocate-2, and ADhere trials published in NEJM 2024. This is not experimental; it is an FDA-approved indication. Plan medical policy [cite policy number and date] has not been updated to reflect this approval. Request immediate review and policy update per [state] insurance code requiring coverage of FDA-approved medications for labeled indications when medically necessary."
• For newer agents (Nemluvio for AD, Zoryve foam for AD): "Nemluvio received FDA approval for atopic dermatitis ages 12+ on December 20, 2024 (prior approval for prurigo nodularis August 2024). Plan policy dated [date] does not list Nemluvio for AD because the policy predates approval. Under [state law / ERISA / Medicare / Medicaid rules], coverage must be provided for FDA-approved on-label uses. ARCADIA-1 and ARCADIA-2 trials demonstrate significant reduction in pruritus (primary endpoint) and EASI improvement."
• Cite guidelines: "AAD 2023 systemic therapy update includes biologics targeting IL-4/13 (Dupixent, Adbry, Ebglyss), IL-31 (Nemluvio), and JAK inhibitors (Cibinqo, Rinvoq) as evidence-based options for moderate-to-severe AD inadequately controlled by topical therapy. These are not experimental—they are guideline-recommended and standard of care."
• If insurer claims "insufficient long-term safety data": "Dupixent has been FDA-approved since March 2017 (over 7 years) with extensive post-marketing surveillance and real-world registries (>600,000 patient-years of exposure). Long-term extension data published in JAMA Dermatology and British Journal of Dermatology confirm sustained efficacy and safety. Conjunctivitis is the most common adverse event (manageable with artificial tears); no increased risk of serious infection, malignancy, or cardiovascular events compared to placebo or conventional immunosuppressants."

Key point: "Experimental" denials are often templated and auto-generated. Attach the FDA approval letter (available on FDA.gov, Drugs@FDA database), the prescribing information, and the NEJM or Lancet trial publication. This usually triggers a manual review by a physician reviewer who will overturn the denial.

---

4. Fighting age or weight restrictions

Concrete steps:

• Cite the FDA label. "Dupixent is FDA-approved for atopic dermatitis in pediatric patients as young as 6 months (approval June 10, 2022). Patient is 18 months old, weighs 11 kg, meets FDA weight-based dosing criteria (10 mg/kg q4wk for <15 kg per label). Plan policy restricting coverage to age ≥12 contradicts FDA labeling and AAD pediatric guidelines. Under [state law], medically necessary FDA-approved treatments cannot be denied based on arbitrary age cutoffs more restrictive than the label."
• For weight: "Ebglyss label requires age ≥12 years and weight ≥40 kg. Patient is 13 years old, 42 kg. Meets both criteria."
• Argue medical necessity for the age group. "Pediatric atopic dermatitis often has greater impact on growth, sleep, school performance, and family quality of life than adult disease (CDLQI score 18). AAD and EADV guidelines support early systemic intervention in children with severe disease to prevent long-term complications (growth stunting from chronic inflammation, psychosocial impairment, increased risk of asthma and allergic comorbidities—'atopic march'). Delaying biologic therapy until age 12 or 18 is not evidence-based and exposes this child to years of corticosteroid-related adverse events (skin atrophy, growth suppression with chronic high-potency TCS) and infectious complications (recurrent S. aureus, eczema herpeticum)."
• Attach pediatric dermatologist letter emphasizing developmental impact, sleep architecture disruption, and school absences.

Key point: Pediatric denials often collapse when you cite the FDA approval date and weight-based dosing table from the label. Include the label as an attachment.

---

5. Fighting duplicate biologic or "not preferred agent" denials

Concrete steps:

• Document the prior biologic trial in detail. "Patient received Dupixent (dupilumab) 300 mg subcutaneous every 2 weeks for 16 weeks (February–May 2024). EASI improved from 28 to 14 (EASI-50 response, not EASI-75). Persistent face and eyelid involvement. Developed grade 2 conjunctivitis (bilateral red eye, tearing, requiring ophthalmology consultation and topical cyclosporine drops). Due to suboptimal response and ocular adverse event, Dupixent was discontinued per shared decision-making with dermatologist and patient."
• Explain mechanism difference. "Dupixent blocks IL-4 receptor alpha, inhibiting both IL-4 and IL-13 signaling. Adbry and Ebglyss selectively block IL-13 only. This mechanistic difference is clinically relevant: patients with inadequate response to dual IL-4/IL-13 blockade may respond to selective IL-13 inhibition, and vice versa. In ECZTRA and ADvocate trials, significant proportions of enrolled patients had prior biologic exposure, and selective IL-13 inhibition was efficacious."
• For IL-31 blockade (Nemluvio): "Patient has severe pruritus despite Dupixent (pruritus NRS remains 8/10 after 16 weeks). Nemluvio targets IL-31 receptor alpha, a distinct pathway specifically mediating itch. ARCADIA-1/2 trials show that nemolizumab significantly reduces pruritus independent of EASI response, addressing the patient's most disabling symptom."
• For JAK inhibitors after biologic failure: "Patient failed Dupixent as above. Cibinqo (JAK1 inhibitor) works via a distinct oral, small-molecule mechanism, blocking Janus kinase signaling downstream of multiple cytokine receptors (IL-4, IL-13, IL-31, TSLP). JADE COMPARE trial demonstrated non-inferiority to Dupixent, and subset analyses show efficacy in biologic-experienced patients. AAD 2023 guidance supports JAK inhibitors as second-line systemic therapy after biologic inadequate response or intolerance."
• Acknowledge safety trade-offs. "Aware of JAK inhibitor boxed warnings (serious infections, malignancy, thrombosis, cardiovascular events per FDA class warning). Patient counseled; benefits outweigh risks given severity of disease, failed topical/phototherapy/biologic options, and functional impairment (unable to work, DLQI 24). Plan to monitor CBC, lipids, and hepatic function per label."

Key point: The insurer's pharmacy benefit manager often has a "preferred biologic" (usually Dupixent because of rebates/contracting). To get a non-preferred agent, you must prove either intolerance or inadequate efficacy to the preferred agent. Your appeal needs the EASI scores at baseline and week 16, the adverse event documentation, and a sentence explaining why switching within the biologic class is evidence-based.

---

What We Do

We help patients and physicians build data-driven appeals that speak the language insurers understand: validated severity scores, guideline citations, detailed treatment timelines, and adverse-event documentation. If you've received a denial for Dupixent, Adbry, Ebglyss, Rinvoq, Cibinqo, Nemluvio, Opzelura, or another atopic dermatitis therapy, we organize your clinical records, draft the physician letter with the specific scoring and trial data your insurer demands, and guide you through each level of appeal (internal, external, state regulators if needed). Our process ensures nothing is missing—because most denials are overturned when the medical record is complete and the guidelines are cited verbatim.

---

Sources

1. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol 2014.

2. American Academy of Dermatology. Atopic dermatitis: Practice update on systemic therapies, Part 2. J Am Acad Dermatol 2023.

3. Wollenberg A, et al. European guideline (EuroGuiDerm) on atopic eczema: part II – systemic therapy. J Eur Acad Dermatol Venereol 2022;36:1904–1926.

4. National Eczema Association. Severity scoring and patient-reported outcome measures (IGA, EASI, POEM, DLQI, Pruritus NRS). Available at nationaleczema.org.

5. FDA prescribing information: Dupixent (dupilumab), Adbry (tralokinumab), Ebglyss (lebrikizumab), Nemluvio (nemolizumab), Cibinqo (abrocitinib), Rinvoq (upadacitinib), Opzelura (ruxolitinib), Eucrisa (crisaborole), Zoryve (roflumilast). Accessed via Drugs@FDA.

6. Simpson EL, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016;375:2335-2348 (SOLO-1, SOLO-2).

7. Silverberg JI, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 2021;184:450–463.

8. Guttman-Yassky E, et al. Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: A Phase 3 Randomized Controlled Trial (ADhere). N Engl J Med 2024 (ADvocate-1, ADvocate-2, ADhere).

9. Ständer S, et al. Nemolizumab in moderate-to-severe prurigo nodularis and atopic dermatitis. N Engl J Med 2024 (ARCADIA-1, ARCADIA-2).

10. Simpson EL, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1 and JADE MONO-2). Lancet 2021;398:850–861.

11. Guttman-Yassky E, et al. Once-daily upadacitinib in moderate-to-severe atopic dermatitis: Week-16 results from the randomized MEASURE UP 1 and MEASURE UP 2 trials. Lancet 2021;397:2151–2168.

12. US Food and Drug Administration. Approval letters and labeling. Drugs@FDA database. Available at www.accessdata.fda.gov/scripts/cder/daf/.